Navigation Links
Pressure BioSciences, Inc. Provides Corporate Update
Date:9/24/2007

WEST BRIDGEWATER, Mass., Sept. 24 /PRNewswire-FirstCall/ -- Pressure BioSciences, Inc. (Nasdaq: PBIO) ("PBI") today provided an update on various corporate activities, including the expansion of its domestic sales force, the listing of its common stock on the Frankfurt Stock Exchange, and reaffirmation of guidance relative to forecasted FY2007 sales of the Company's Barocycler instruments.

1) Domestic Sales Force: the Company has hired four U.S. regional sales directors over the past month, increasing to six the number of full-time sales personnel it now has in the field. These four individuals all have strong educational backgrounds in the biological sciences, many years of experience working in (and often supervising) genomic or proteomic laboratories, and experience in selling capital equipment and/or consumable supplies into the research marketplace. The Company expects to hire at least one additional regional sales director during the next few weeks.

2) Frankfurt Stock Exchange: the Company's common stock is now listed on the Frankfurt Stock Exchange (FSE) with a trading symbol of BII.FSE and a WKN (German Security Code) of A0DJ09. The Frankfurt Stock Exchange is the third largest stock exchange in the world; shares traded on the FSE do not affect the Company's total shares outstanding.

3) Guidance on Barocycler Sales: the Company has reaffirmed its previously announced guidance concerning the Company's expectation to install a minimum of twenty (20) Barocycler units during the 2007 fiscal year.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded company focused on the development of a novel, enabling, platform technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 5 foreign patents covering multiple applications of PCT in the life sciences field, including such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of chemical reactions (particularly enzymes), immunodiagnostics, and protein purification.

Forward Looking Statements

Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements include statements regarding the Company's expansion of its sales force; its listing on the Frankfurt Stock Exchange; and expected installations of Barocycler instruments during fiscal year 2007. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: the possibility that the Company may not be successful in retaining the sales personnel that it has recently hired, or recruiting and retaining additional qualified sales personnel; the possibility that the Company may not be successful in maintaining a listing on the Frankfurt Stock Exchange, or that such listing may not be beneficial to the Company and its stockholders; risks and uncertainties concerning new product development, including the possibility that the Company may encounter unforeseen technological difficulties in the development of the PCT technology, the possibility that the Company's PCT products may not be accepted by the commercial market as a needed improvement over current extraction methods, or other difficulties that would prevent or otherwise impair the Company's ability to install at least twenty Barocycler units in fiscal year 2007; and the other risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

Visit us at our website http://www.pressurebiosciences.com

Investor Contacts:

Richard T. Schumacher, President & CEO

Edward H. Myles, Sr. Vice President of Finance & CFO

Pressure BioSciences, Inc.

(508) 580-1818 (T)


'/>"/>
SOURCE Pressure BioSciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. The Analysis of Polycyclic Aromatic Hydrocarbons (PAHs) by LC/MS/MS Using an Atmospheric Pressure Photoionization Source
2. Determination of N-nitrosamines in Baby Bottle Rubber Teats by Liquid Chromatography-Atmospheric Pressure Chemical Ionization Mass Spectrometry
3. Screening of Corticosteroids in Urine by Negative Atmospheric Pressure Chemical Ionization LC/MS/MS
4. Medical College receives $11 million grant to study high blood pressure
5. Pressure mounts for Doyle to repeal shareholder liability law
6. Probe into gas gouging may educate Americans about pressures on oil supply
7. SWIB gets more pressure to invest in state tech start-ups
8. Technology puts pressure on old education methods
9. Effectene Transfection Reagent provides efficient gene delivery to primary neuronal cell cultures
10. TSKgel ODS-100Z and TSKgel ODS-100V column series provides a universal solution for the analysis of samples containing acidic, basic, polar & non-polar compounds
11. State provides $200K for Necedah ethanol plant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016 Epic Sciences ... detects cancers susceptible to PARP inhibitors by targeting ... cells (CTCs). The new test has already been ... in multiple cancer types. Over 230 ... damage response pathways, including PARP, ATM, ATR, DNA-PK ...
(Date:6/23/2016)... 2016   Boston Biomedical , an industry ... to target cancer stemness pathways, announced that its ... Drug Designation from the U.S. Food and Drug ... including gastroesophageal junction (GEJ) cancer. Napabucasin is an ... cancer stemness pathways by targeting STAT3, and is ...
(Date:6/23/2016)... Prostate Cancer Foundation (PCF) is pleased to announce 24 new Young Investigator ... Members of the Class of 2016 were selected from a pool of 128 ... About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... , ... June 23, 2016 , ... In a new ... in Denmark detail how a patient who developed lymphedema after being treated for breast ... results could change the paradigm for dealing with this debilitating, frequent side effect of ...
Breaking Biology Technology:
(Date:5/16/2016)... 16, 2016   EyeLock LLC , a market ... opening of an IoT Center of Excellence in ... the development of embedded iris biometric applications. ... convenience and security with unmatched biometric accuracy, making it ... from DNA. EyeLock,s platform uses video technology to deliver ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 ... of Infosys (NYSE: INFY ), and Samsung SDS, ... partnership that will provide end customers with a more ... payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) ... financial services, but it also plays a fundamental part in ...
(Date:4/19/2016)... , UAE, April 20, 2016 ... implemented as a compact web-based "all-in-one" system solution for ... biometric fingerprint reader or the door interface with integration ... modern access control systems. The minimal dimensions of the ... readers into the building installations offer considerable freedom of ...
Breaking Biology News(10 mins):